Survival after cardiac arrest or sustained ventricular tachycardia in patients with hypertrophic cardiomyopathy

Journal of the American College of Cardiology

Volumn 33, Issue 6, 1999, Pages 1596-1601

  Elliott, Perry M ^a,b   Sharma, Sanjay ^a   Varnava, Amanda ^a   Poloniecki, Jan ^a   Rowland, Edward ^a   McKenna, William J ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE MONITORING; CHILD; CLINICAL ARTICLE; DEFIBRILLATOR; HEART ARREST; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; MALE; NEUROLOGIC DISEASE; PRIORITY JOURNAL; SURVIVAL TIME;

ADOLESCENT; ADULT; AMIODARONE; ANTI-ARRHYTHMIA AGENTS; CARDIOMYOPATHY, HYPERTROPHIC; CHILD; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; DNA MUTATIONAL ANALYSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HEART ARREST; HUMANS; MALE; PROSPECTIVE STUDIES; RESUSCITATION; SARCOMERES; SURVIVAL RATE; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 0033133591     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00056-X     Document Type: Article

References (31)

1. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
2. McKenna WJ, Deanfield J, Faruqui A, England D, Oakley C, Goodwin J. Prognosis m hypertrophic cardiomyopathy. Role of age and clinical, electrocardiographic and haemodynamic features. Am J Cardiol 1981;47:532-8.
3. McKenna WJ, Franklin RCG, Nihoyannopoulos P, Robinson KC, Deanfield JE. Arrhythmia and prognosis in infants, children and adolescents with hypertrophic cardiomyopathy. J Am Coll Cardiol 1988;11:147-53.
4. Spirito P, Chiarella F, Carratino L, Zoni-Berisso M, Bellotti P, Vecchio C. Clinical course and prognosis of hypertrophic cardiomyopathy in an outpatients population. N Engl J Med 1989;320:749-55.
5. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529-36.
6. Cannan CR, Reeder GS, Bailey KR, Melton LJ, Gersh BJ. Natural history of hypertrophic cardiomyopathy. A population based study, 1976 through 1990. Circulation 1995;92:2488-95.
7. Cecchi F, Maron BJ, Epstein SE. Long-term outcome of patients with hypertrophic cardiomyopathy successfully resuscitated after cardiac arrest. J Am Coll Cardiol 1989;13:1283-8.
8. Anan R, Greve G, Thierfelder L, et al. Prognostic implications of novel beta cardiac myosin heavy chain gene mutations that cause familial hypertrophic cardiomyopathy. J Clin Invest 1994;93:280-5.
9. Watkins H, McKenna WJ, Thierfelder L, et al. Mutations in the genes for cardiac troponin T and alpha-tropomyosm in hypertrophic cardiomyopathy. N Engl J Med 1995;332:1058-64.
10. Watkins H, Rosenzweig A, Hwang DS, et al. Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy. N Engl J Med 1992;326:1108-14.
11. Thierfelder L, Watkins H, MacRae C, et al. Alpha-tropomyosin and cardiac troponin T mutations cause familial hypertrophic cardiomyopathy: a disease of the sarcomere. Cell 1994;77:701-12.
12. Shapiro LM, McKenna WJ. Distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a two dimensional echocardiographic study. J Am Coll Cardiol 1983;2:437-44.
13. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418-28.
14. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task force on the definition and classification of cardiomyopathies. Circulation 1996;93:841-2.
15. Chikamori T, Counihan PJ, Doi YL, et al. Mechanisms of exercise limitation in hypertrophic cardiomyopathy. J Am Coll Cardiol 1992; 19:507-12.
16. Frenneaux MP, Counihan PJ, Caforio A, Chikamori T, McKenna WJ. Abnormal blood pressure response during exercise in hypertrophic cardiomyopathy. Circulation 1990;82:1995-2002.
17. McKenna WJ, England D, Doi Y, Deanfield JE, Oakley CM, Goodwin JF. Arrhythmia in hypertrophic cardiomyopathy. 1. Influence on prognosis. Br Heart J 1981;46:168-72.
18. Maron BJ, Savage DD, Wolfson JK, Epstein SE. Prognostic significance of 24 hour ambulatory electrocardiographic monitoring in patients with hypertrophic cardiomyopathy: a prospective study. Am J Cardiol 1981;48:252-7.
19. Sadoul N, Prasad K, Elliott PM, Banerjee S, Frenneaux MP, McKenna WJ. Prospective prognostic assessment of blood pressure response during exercise in patients with hypertrophic cardiomyopathy. Circulation 1997;96:2987-91.
20. Counihan PJ, Frenneaux MP, Webb DJ, McKenna WJ. Abnormal vascular responses to supine exercise in hypertrophic cardiomyopathy. Circulation 1991;84:686-96.
21. Monseratt L, Elliott P, Prasad K, Penas-Lado M, Castro-Beiras A, McKenna WJ. Non-sustained ventricular tachycardia and sudden death in hypertrophic cardiomyopathy (abstr). J Am Coll Cardiol 1998;31 Suppl:26A.
22. Stafford WJ, Trohman RG, Busker M, Zaman L, Catellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atnal fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;7: 701-4.
23. Nicod P, Polikar R, Peterson KL. Hypertrophic cardiomyopathy and sudden death. N Engl J Med 1988;318:1255-7.
24. Kron J, Oliver RP, Norsted S, Silka MJ. The automatic implantable cardioverter-defibrillator in young patients. J Am Coll Cardiol 1990; 16:896-902.
25. Silka MJ, Kron J, Dunnigan A, Dick M. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. Circulation 1993;87:800-7.
26. Primo J, Geelen P, Brugada J, et al. Hypertrophic cardiomyopathy: role of the implantable cardioverter defibrillator. J Am Coll Cardiol 1998;31:1081-5.
27. Borgreffe M, Breithardt G. Is the implantable defibrillator indicated in patients with hypertrophic cardiomyopathy and aborted sudden death? J Am Coll Cardiol 1998;31:1086-8.
28. Zhu D, Sun H, Hill R, Roberts R. The value of electrophysiology study and prophylactic implantation of cardioverter defibrillator in patients with hypertrophic cardiomyopathy. PACE Pacing Clin Electrophysiol 1998;21:299-302.
29. McKenna WJ, Oakley CM, Krikler DM, et al. Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985;53:412-6.
30. Fananapazir L, Leon MB, Bonow RO, Tracy CM, Cannon RO, Epstein SE. Sudden death during empiric amiodarone therapy in symptomatic hypertrophic cardiomyopathy. Am J Cardiol 1991;67: 169-74.
31. Elliott PM, Poloniecki J, Sharma S, Dickie S, McKenna WJ. Amiodarone and sudden death in patients with hypertrophic cardiomyopathy (abstr). Heart 1998;79:3.